ONC201 FOR H3K27M-MUTANT
DIFFUSE MIDLINE GLIOMA
The first targeted therapy FDA-approved specifically for H3K27M-mutant diffuse midline glioma — including DIPG — marking a historic shift in a disease that previously had no approved treatment beyond radiotherapy.
analyticsAt a Glance
- check_circleONC201 received FDA accelerated approval in 2024 for H3K27M-mutant diffuse midline glioma after prior RT
- check_circleH3K27M mutation defines diffuse midline glioma WHO grade 4 — present in >80% of DIPG cases
- check_circleONC201 is an oral once-weekly agent that activates the mitochondrial protease ClpP and antagonises DRD2
- check_circleCancerFax assists international patients with ONC201 eligibility review, access pathways, and clinical trial matching
What Is H3K27M-Mutant Diffuse Midline Glioma?
Diffuse midline glioma, H3K27M-mutant (DMG) is a WHO grade 4 brain tumour defined by its location (thalamus, brainstem, spinal cord, or other midline structures) and by the presence of a histone H3 lysine 27 methionine substitution (H3 K27M). This mutation profoundly disrupts epigenetic regulation, driving an aggressive infiltrative biology with historically dismal outcomes.
“H3K27M is not just a mutation — it is a molecular diagnosis that defines both the tumour's biology and, now, its specific treatment vulnerability.”
DIPG: H3K27M in the Brainstem
Diffuse intrinsic pontine glioma (DIPG) is the most common H3K27M-mutant DMG — arising in the pons. It accounts for 10–15% of all paediatric brain tumours and was previously uniformly fatal within 12–15 months of diagnosis.
H3K27M Testing
H3K27M mutation is detected by immunohistochemistry (anti-H3K27M antibody) or DNA sequencing from biopsy tissue. Liquid biopsy (CSF cell-free DNA) is increasingly used when biopsy is not feasible — particularly for brainstem DMG where surgical access is limited.
ONC201 Clinical Trial Data: Key Numbers
The pivotal data supporting FDA accelerated approval came from the ACTION study (H3-matched monotherapy cohort) and supporting expansion cohorts.
- 25%Objective response rate in H3K27M-mutant DMG (ACTION study)ONC201 monotherapy achieved an ORR of ~25% in post-RT H3K27M-mutant DMG — meaningful in a disease where no approved treatment existed and median OS was previously 12–15 months.
- 21.7 moMedian OS in ONC201-treated H3K27M-mutant thalamic DMG cohortThalamic DMG patients treated with ONC201 showed a median OS of 21.7 months from diagnosis in an expanded cohort analysis — substantially longer than historical controls.
- Once weeklyONC201 dosing schedule (440 mg oral)ONC201 is taken orally at 440 mg once per week — a manageable schedule for an outpatient setting with generally mild side effects compared to cytotoxic chemotherapy.
ONC201 Eligibility and Access Pathway
FDA-approved ONC201 (brand name Ojemda, Chimerix Inc.) is available in the USA. International access requires identifying the correct pathway — expanded access, named-patient, or clinical trial.
- 1
Confirm H3K27M Mutation Status
H3K27M immunohistochemistry on tumour tissue is required. If biopsy has not been performed, CSF ctDNA or liquid biopsy H3K27M detection may support eligibility in select protocols — discuss with a specialist centre.
- 2
Confirm Prior Radiotherapy
The FDA-approved indication specifies H3K27M-mutant DMG after prior radiotherapy. Patients who have not received RT require treatment initiation with RT before ONC201 can be given per the approved label.
- 3
Identify Access Route by Country
USA: FDA-approved, commercially available. Europe: EMA review ongoing — named-patient access via Chimerix compassionate use programme. Asia/India/MENA: expanded access or clinical trial. CancerFax maps the correct route for each patient's geography.
- 4
Clinical Trial Consideration
ONC201 is active in multiple ongoing trials — PNOC022, ACTION II, and combination trials with RT or other targeted agents. Trial access may be the best option for patients outside the USA, particularly for newly diagnosed DMG.
- 5
Treatment and Monitoring
ONC201 is continued until progression or unacceptable toxicity. Monitoring includes MRI every 8–12 weeks and clinical assessment. Pseudo-progression is observed in some patients early in treatment — distinguish from true progression before stopping.
ONC201 Clinical Outcomes vs Historical Controls
Direct comparison of ONC201-treated H3K27M DMG outcomes against historical controls — showing meaningful improvement in a disease previously considered universally lethal.
Median Overall Survival — H3K27M-Mutant DMG
Source: ACTION study and expanded cohort data presented at SNO 2023; historical control data from PNOC/DIPG registry
- ONC201 — Thalamic DMG (expanded cohort)21.7 months
- ONC201 — All H3K27M DMG (ACTION)~15.7 months
- Historical control — H3K27M DMG~12.5 months
- Historical control — DIPG (brainstem)~10–11 months
ONC201: Favourable Factors vs Points to Discuss with Your Team
ONC201 is the first approved targeted therapy for H3K27M DMG — but understanding who benefits most and what the limitations are is critical for informed decision-making.
Favourable for ONC201
- H3K27M mutation confirmedH3K27M IHC or sequencing confirms the molecular target — ONC201 is specifically active against H3K27M-mutant biology via ClpP activation and DRD2 antagonism.
- Post-radiotherapy settingThe approved indication is for DMG after prior RT — consistent with the clinical trial population and the practical reality that RT remains the first line of treatment for most DMG patients.
- Thalamic DMG locationPublished cohort data suggests thalamic DMG may respond better than brainstem DMG to ONC201 — median OS in thalamic cases exceeds 21 months in expanded cohort data.
Points Requiring Specialist Discussion
- DIPG / brainstem location — more modest benefitBrainstem DMG shows lower ORR to ONC201 than thalamic cases. It remains the best available option but families should have accurate expectations about the magnitude of benefit.
- Pseudo-progression monitoring requiredEarly MRI worsening on ONC201 does not always represent true progression — pseudo-progression is well-documented. Stopping ONC201 prematurely for apparent imaging progression may deprive patients of benefit.
- International access is complexOutside the USA, ONC201 is not commercially available. Named-patient, compassionate use, or clinical trial are the routes — each with different timelines, cost structures, and requirements. CancerFax navigates this for international families.
Frequently Asked Questions
Common questions from patients and families navigating H3K27M DMG and ONC201 access.
About ONC201 and DMG
Does ONC201 work for DIPG specifically?
ONC201 shows activity in DIPG (H3K27M-mutant pontine DMG), but the published response data is more modest for brainstem tumours than for thalamic DMG. A meaningful proportion of DIPG patients show radiographic response or stable disease — and the drug is the only FDA-approved targeted therapy for this diagnosis. All patients with H3K27M-mutant DIPG after RT should be considered for ONC201.
How do I access ONC201 outside the USA?
CancerFax assists families in identifying the most viable pathway: (1) Chimerix expanded access/compassionate use programme — available in selected countries; (2) clinical trial enrolment — ONC201 trials are open in Europe, Canada, and Australia; (3) import via licensed pharmacy for named-patient use in some countries. The pathway depends on the patient's country of residence and disease status.
Can ONC201 be combined with other treatments?
Yes — combination trials are ongoing. ONC201 + reirradiation, ONC201 + ONC206 (a next-generation imipridone), and ONC201 + panobinostat are among the combinations being evaluated. For newly diagnosed H3K27M DMG, ONC201 with upfront RT is being studied in the ACTION II trial. CancerFax can identify open combination trials for eligible patients.
What are ONC201's side effects?
ONC201 is generally well tolerated. The most common adverse events are fatigue, nausea, and diarrhoea — typically grade 1–2. Significant haematological or organ toxicities are uncommon at the approved 440 mg weekly dose. The tolerability profile supports long-term continuous administration.
More from the Brain Tumour Treatment Resource Library
Explore related guides on brain tumour targeted therapy, treatment access, and specialist centres.
- ↑ Brain Tumour Treatment — Complete Guide
- Vorasidenib for IDH-Mutant Grade 2 Glioma: The INDIGO Trial
- Brain Tumour Treatment in China: Tiantan Hospital Beijing and SPHIC
- Getting a Second Opinion on Brain Tumour Treatment Through CancerFax
- Medulloblastoma in Children: Molecular Subgroups, Treatment, and Outcomes
- Brain Tumour Treatment Costs: China vs India vs USA
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is ONC201 an Option for Your Diffuse Midline Glioma?
CancerFax reviews H3K27M mutation status, prior treatment history, and current disease status to confirm ONC201 eligibility — and identifies access pathways including FDA-approved supply, expanded access, named-patient programmes, and ongoing clinical trials for international patients.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified neuro-oncologist before making treatment decisions.